1. Home
  2. NAMS vs HUN Comparison

NAMS vs HUN Comparison

Compare NAMS & HUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • HUN
  • Stock Information
  • Founded
  • NAMS 2019
  • HUN 1970
  • Country
  • NAMS Netherlands
  • HUN United States
  • Employees
  • NAMS N/A
  • HUN N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • HUN Major Chemicals
  • Sector
  • NAMS Health Care
  • HUN Industrials
  • Exchange
  • NAMS Nasdaq
  • HUN Nasdaq
  • Market Cap
  • NAMS 2.5B
  • HUN 2.4B
  • IPO Year
  • NAMS N/A
  • HUN 2005
  • Fundamental
  • Price
  • NAMS $19.85
  • HUN $11.15
  • Analyst Decision
  • NAMS Strong Buy
  • HUN Hold
  • Analyst Count
  • NAMS 8
  • HUN 9
  • Target Price
  • NAMS $42.88
  • HUN $15.00
  • AVG Volume (30 Days)
  • NAMS 1.0M
  • HUN 3.8M
  • Earning Date
  • NAMS 08-06-2025
  • HUN 08-04-2025
  • Dividend Yield
  • NAMS N/A
  • HUN 9.00%
  • EPS Growth
  • NAMS N/A
  • HUN N/A
  • EPS
  • NAMS N/A
  • HUN N/A
  • Revenue
  • NAMS $47,140,000.00
  • HUN $5,976,000,000.00
  • Revenue This Year
  • NAMS N/A
  • HUN N/A
  • Revenue Next Year
  • NAMS N/A
  • HUN $5.10
  • P/E Ratio
  • NAMS N/A
  • HUN N/A
  • Revenue Growth
  • NAMS 586.97
  • HUN 0.02
  • 52 Week Low
  • NAMS $14.06
  • HUN $10.13
  • 52 Week High
  • NAMS $27.29
  • HUN $25.12
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 52.90
  • HUN 51.57
  • Support Level
  • NAMS $17.97
  • HUN $10.30
  • Resistance Level
  • NAMS $19.13
  • HUN $11.39
  • Average True Range (ATR)
  • NAMS 1.04
  • HUN 0.42
  • MACD
  • NAMS -0.03
  • HUN 0.13
  • Stochastic Oscillator
  • NAMS 35.63
  • HUN 73.25

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About HUN Huntsman Corporation

Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. It derives the majority of its revenue from the Polyurethanes segment,t which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.

Share on Social Networks: